Larimar Therapeutics (LRMR) 8-K Summary

Event: Filing reports financial results and operational highlights for the third quarter ended September 30, 2025.

• This Form 8-K primarily serves to furnish the related press release (Exhibit 99.1).
• Investors must review Exhibit 99.1 for specific Q3 financial performance metrics and operational updates.

Note: Information furnished under Item 2.02 is generally not deemed “filed” under Section 18 liability unless explicitly incorporated elsewhere.

Key Takeaway: Q3 2025 earnings announcement has occurred as of November 5,